
Merck & Co., Inc.
MRKHealthcare|Drug Manufacturers - General|US
$146.71
-0.23 (-0.16%)
DCF Value
$180.27
Graham Number
$20.09
Cash / Share
$3.89
Financials
Financial Snapshot
Market Cap
$361.96B
Enterprise Value
$406.19B
Revenue (TTM)
$67.30B
Net Income (TTM)
$2.45B
Cash & Investments
$9.65B
Net Cash
-$44.13B
Free Cash Flow (TTM)
$14.75B
Operating CF (TTM)
$18.70B
Debt/Equity
1.20
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $14.34B | $8.50B | $8.86B | $10.45B | $8.05B | $8.10B | $13.19B | $7.09B | $13.69B | $14.56B | $9.65B | |
| Operating Cash Flow | $10.38B | $6.45B | $10.92B | $13.44B | $10.25B | $14.11B | $19.09B | $13.01B | $21.47B | $16.47B | $18.70B | |
| Free Cash Flow | $8.76B | $4.56B | $8.31B | $9.97B | $5.82B | $9.66B | $14.71B | $9.14B | $18.10B | $12.36B | $14.75B | |
| Capital Expenditure | -$1.61B | -$1.89B | -$2.62B | -$3.47B | -$4.43B | -$4.45B | -$4.39B | -$3.86B | -$3.37B | -$4.11B | -$3.96B | |
| Financing Cash Flow | -$9.04B | -$10.01B | -$13.16B | -$8.86B | -$2.83B | $2.59B | -$9.12B | -$4.81B | -$7.03B | -$1.92B | $1.10B |
R&D Spending
R&D (TTM)
$29.33B
R&D Intensity
43.6%
R&D Growth vs Prior
+134.4%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.81B | $40.12B | $42.29B | $39.12B | $41.52B | $48.70B | $59.28B | $60.12B | $64.17B | $64.93B | $67.30B | |
| R&D Expense | $10.26B | $10.34B | $9.75B | $9.72B | $13.40B | $12.24B | $13.55B | $30.53B | $17.94B | $12.51B | $29.33B | |
| R&D % of Revenue | 25.8% | 25.8% | 23.1% | 24.9% | 32.3% | 25.1% | 22.9% | 50.8% | 28.0% | 19.3% | 43.6% | |
| SG&A | $10.02B | $10.07B | $10.10B | $9.46B | $8.57B | $9.40B | $9.67B | $9.88B | $10.10B | $10.73B | $11.28B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.81B | $40.12B | $42.29B | $39.12B | $41.52B | $48.70B | $59.28B | $60.12B | $64.17B | $64.93B | $67.30B | |
| Cost of Revenue | $14.03B | $12.91B | $13.51B | $12.02B | $13.62B | $13.63B | $17.41B | $16.13B | $15.19B | $18.20B | $15.51B | |
| Gross Profit | $25.78B | $27.21B | $28.79B | $27.11B | $27.90B | $35.08B | $41.87B | $43.99B | $48.98B | $46.73B | $51.79B | |
| R&D | $10.26B | $10.34B | $9.75B | $9.72B | $13.40B | $12.24B | $13.55B | $30.53B | $17.94B | $12.51B | $29.33B | |
| SG&A | $10.02B | $10.07B | $10.10B | $9.46B | $8.57B | $9.40B | $9.67B | $9.88B | $10.10B | $10.73B | $11.28B | |
| Operating Income | $5.50B | $6.80B | $8.93B | $7.93B | $5.55B | $13.20B | $18.28B | $2.95B | $20.22B | $23.49B | $10.93B | |
| Interest Expense | $693.0M | $754.0M | $772.0M | $893.0M | $831.0M | $806.0M | $962.0M | $1.15B | $1.27B | $1.36B | $936.0M | |
| Pretax Income | $4.66B | $6.52B | $8.70B | $7.17B | $5.86B | $13.88B | $16.44B | $1.89B | $19.94B | $21.07B | $4.76B | |
| Net Income | $3.92B | $2.39B | $6.22B | $9.84B | $7.07B | $13.05B | $14.52B | $365.0M | $17.12B | $18.25B | $2.45B | |
| EPS (Diluted) | 2.04 | 0.93 | 2.32 | 3.82 | 2.78 | 5.14 | 5.71 | 0.14 | 6.74 | 7.28 | 0.97 | |
| EBITDA | $10.82B | $11.95B | $13.99B | $16.01B | $10.18B | $17.90B | $21.32B | $6.91B | $25.71B | $28.26B | $13.03B | |
| Shares Out. (M) | 2787.00 | 2748.00 | 2679.00 | 2580.00 | 2541.00 | 2538.00 | 2542.00 | 2547.00 | 2541.00 | 2507.00 | 2478.00 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.51B | $6.09B | $7.96B | $9.68B | $8.05B | $8.10B | $12.69B | $6.84B | $13.24B | $14.56B | $9.55B | |
| Short-Term Investments | $7.83B | $2.41B | $899.0M | $774.0M | $0.00 | $0.00 | $498.0M | $252.0M | $447.0M | $0.00 | $100.0M | |
| Total Current Assets | $30.61B | $24.77B | $25.88B | $27.48B | $27.76B | $30.27B | $35.72B | $32.17B | $38.78B | $43.52B | $38.94B | |
| Total Assets | $95.38B | $87.87B | $82.64B | $84.40B | $91.59B | $105.69B | $109.16B | $106.67B | $117.11B | $136.87B | $132.77B | |
| Total Current Liabilities | $17.20B | $18.61B | $22.21B | $22.22B | $27.33B | $23.87B | $24.24B | $25.69B | $28.42B | $28.33B | $28.80B | |
| Long-Term Debt | $24.27B | $21.35B | $19.81B | $22.74B | $25.36B | $30.69B | $28.75B | $33.68B | $34.46B | $46.75B | $49.69B | |
| Total Liabilities | $55.07B | $53.30B | $55.76B | $58.40B | $66.18B | $67.44B | $63.10B | $69.04B | $70.73B | $84.20B | $87.83B | |
| Stockholders' Equity | $40.09B | $34.34B | $26.70B | $25.91B | $25.32B | $38.18B | $45.99B | $37.58B | $46.31B | $52.61B | $44.89B | |
| Retained Earnings | $44.13B | $41.35B | $42.58B | $46.60B | $47.36B | $53.70B | $61.08B | $53.90B | $63.07B | $73.08B | $66.22B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $10.38B | $6.45B | $10.92B | $13.44B | $10.25B | $14.11B | $19.09B | $13.01B | $21.47B | $16.47B | $18.70B | |
| Capital Expenditure | -$1.61B | -$1.89B | -$2.62B | -$3.47B | -$4.43B | -$4.45B | -$4.39B | -$3.86B | -$3.37B | -$4.11B | -$3.96B | |
| Free Cash Flow | $8.76B | $4.56B | $8.31B | $9.97B | $5.82B | $9.66B | $14.71B | $9.14B | $18.10B | $12.36B | $14.75B | |
| Investing Cash Flow | -$3.21B | $2.68B | $4.31B | -$2.63B | -$9.44B | -$16.55B | -$4.96B | -$14.08B | -$7.73B | -$13.74B | -$28.33B | |
| Financing Cash Flow | -$9.04B | -$10.01B | -$13.16B | -$8.86B | -$2.83B | $2.59B | -$9.12B | -$4.81B | -$7.03B | -$1.92B | $1.10B | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $384.0M | $0.00 | $0.00 | $92.0M | $494.0M | |
| Repurchase of Stock | -$3.43B | -$4.01B | -$9.09B | -$4.78B | -$1.28B | -$840.0M | $0.00 | -$1.35B | -$1.31B | -$5.08B | -$3.54B | |
| Net Debt Issuance | -$1.31B | -$1.13B | $837.0M | $1.25B | $5.01B | $1.63B | -$2.25B | $4.18B | $2.31B | $11.38B | $12.66B | |
| Stock Based Comp. | $300.0M | $312.0M | $348.0M | $417.0M | $441.0M | $479.0M | $541.0M | $645.0M | $761.0M | $0.00 | $1.06B | |
| Net Change in Cash | -$2.01B | -$423.0M | $1.87B | $1.97B | -$1.77B | $14.0M | $4.61B | -$5.86B | $6.41B | $1.37B | -$8.55B |
Dilution Tracker
Shares Outstanding
2467M
5-Year Share Growth
-1.3%
Stock Issuance (TTM)
$494.0M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 2787.00 | 2748.00 | 2679.00 | 2580.00 | 2541.00 | 2538.00 | 2542.00 | 2547.00 | 2541.00 | 2507.00 | 2478.00 | |
| Change vs Prior % | — | -1.4% | -2.5% | -3.7% | -1.5% | -0.1% | 0.2% | 0.2% | -0.2% | -1.3% | -1.2% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $384.0M | $0.00 | $0.00 | $92.0M | $494.0M | |
| Stock Repurchase | -$3.43B | -$4.01B | -$9.09B | -$4.78B | -$1.28B | -$840.0M | $0.00 | -$1.35B | -$1.31B | -$5.08B | -$3.54B | |
| Stock Based Comp. | $300.0M | $312.0M | $348.0M | $417.0M | $441.0M | $479.0M | $541.0M | $645.0M | $761.0M | $0.00 | $1.06B |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 64.8% | 67.8% | 68.1% | 69.3% | 67.2% | 72.0% | 70.6% | 73.2% | 76.3% | 72.0% | 77.0% | |
| Operating Margin % | 13.8% | 16.9% | 21.1% | 20.3% | 13.4% | 27.1% | 30.8% | 4.9% | 31.5% | 36.2% | 16.2% | |
| Net Margin % | 9.8% | 6.0% | 14.7% | 25.2% | 17.0% | 26.8% | 24.5% | 0.6% | 26.7% | 28.1% | 3.6% | |
| EBITDA Margin % | 27.2% | 29.8% | 33.1% | 40.9% | 24.5% | 36.8% | 36.0% | 11.5% | 40.1% | 43.5% | 19.4% | |
| FCF Margin % | 22.0% | 11.4% | 19.6% | 25.5% | 14.0% | 19.8% | 24.8% | 15.2% | 28.2% | 19.0% | 21.9% | |
| ROE % | 9.8% | 7.0% | 23.3% | 38.0% | 27.9% | 34.2% | 31.6% | 1.0% | 37.0% | 34.7% | 5.3% | |
| ROA % | 4.1% | 2.7% | 7.5% | 11.7% | 7.7% | 12.3% | 13.3% | 0.3% | 14.6% | 13.3% | 1.8% | |
| ROIC % | 5.9% | 3.5% | 9.7% | 9.4% | 6.0% | 13.9% | 18.5% | 0.7% | 19.0% | 18.3% | 5.2% | |
| R&D / Revenue % | 25.8% | 25.8% | 23.1% | 24.9% | 32.3% | 25.1% | 22.9% | 50.8% | 28.0% | 19.3% | 43.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.8% | 0.8% | 5.4% | -7.5% | 6.1% | 17.3% | 21.7% | 1.4% | 6.7% | 1.2% | |
| Gross Profit | 4.9% | 5.6% | 5.8% | -5.8% | 2.9% | 25.7% | 19.4% | 5.1% | 11.3% | -4.6% | |
| Operating Income | -27.1% | 23.6% | 31.4% | -11.3% | -30.0% | 137.9% | 38.5% | -83.8% | 584.5% | 16.1% | |
| Net Income | -11.8% | -38.9% | 159.8% | 58.2% | -28.2% | 84.6% | 11.3% | -97.5% | 4589.6% | 6.6% | |
| EPS (Diluted) | 30.8% | -54.4% | 149.5% | 64.7% | -27.2% | 84.9% | 11.1% | -97.5% | 4714.3% | 8.0% | |
| Operating Cash Flow | -16.5% | -37.9% | 69.4% | 23.1% | -23.7% | 37.6% | 35.3% | -31.9% | 65.1% | -23.3% | |
| Free Cash Flow | -22.2% | -47.9% | 82.1% | 20.0% | -41.6% | 65.9% | 52.2% | -37.8% | 97.9% | -31.7% | |
| R&D Expense | 53.1% | 0.8% | -5.7% | -0.3% | 37.8% | -8.6% | 10.6% | 125.4% | -41.2% | -30.2% | |
| SG&A Expense | -2.9% | 0.6% | 0.3% | -6.4% | -9.4% | 9.7% | 2.8% | 2.2% | 2.2% | 6.2% | |
| Total Assets | -6.2% | -7.9% | -6.0% | 2.1% | 8.5% | 15.4% | 3.3% | -2.3% | 9.8% | 16.9% | |
| Book Value / Share | -8.9% | -12.6% | -19.1% | -2.2% | -0.9% | 50.6% | 20.3% | -18.8% | 23.9% | 14.9% | |
| Debt | -5.9% | -1.7% | 2.9% | 8.9% | 22.2% | 3.6% | -7.6% | 13.4% | 5.5% | 32.0% | |
| Diluted Shares | -1.9% | -1.4% | -2.5% | -3.7% | -1.5% | -0.1% | 0.2% | 0.2% | -0.2% | -1.3% |
Valuation
P/E (TTM)149.70
10Y Low / Med / High14.42 / 27.12 / 778.71
P/S5.38
10Y Low / Med / High3.61 / 4.47 / 5.69
P/B8.10
10Y Low / Med / High3.85 / 6.11 / 8.59
EV/EBITDA31.16
10Y Low / Med / High10.59 / 14.73 / 44.46
EV/Revenue6.04
10Y Low / Med / High4.06 / 4.87 / 6.14
P/FCF24.55
10Y Low / Med / High13.92 / 22.32 / 33.88
Intrinsic Value Models (per share)
DCF Value
$180.27
Graham Number
$20.09
Cash / Share
$3.89
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 27.12 | 56.47 | 30.36 | 22.58 | 27.96 | 14.85 | 19.36 | 778.71 | 14.72 | 14.42 | 149.70 | |
| P/S Ratio | 3.88 | 3.61 | 4.47 | 5.69 | 4.75 | 3.98 | 4.74 | 4.62 | 3.93 | 4.06 | 5.38 | |
| P/B Ratio | 3.85 | 4.21 | 7.07 | 8.59 | 7.79 | 5.08 | 6.11 | 7.39 | 5.44 | 5.01 | 8.10 | |
| EV/EBITDA | 15.95 | 13.64 | 14.73 | 15.00 | 21.88 | 12.32 | 14.08 | 44.46 | 10.77 | 10.59 | 31.16 | |
| EV/Revenue | 4.34 | 4.06 | 4.87 | 6.14 | 5.36 | 4.53 | 5.06 | 5.11 | 4.32 | 4.61 | 6.04 |
Analyst Estimates & Quality
Altman Z-Score
3.96
Safe
Piotroski F-Score
6
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $67.22B | $69.42B | $73.58B |
| Net Income | $6.89B | $22.20B | $24.48B |
| EPS | $2.77 | $8.91 | $9.92 |
| # Analysts (EPS) | 14 | 14 | 8 |
Dividends
Dividend/Share (TTM)
$3.40
Dividend Yield
2.32%
Frequency
Quarterly
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Sep 15, 2026 | Oct 7, 2026 | $0.85 | Quarterly |
| Jun 15, 2026 | Jul 8, 2026 | $0.85 | Quarterly |
| Mar 16, 2026 | Apr 7, 2026 | $0.85 | Quarterly |
| Dec 15, 2025 | Jan 8, 2026 | $0.85 | Quarterly |
| Sep 15, 2025 | Oct 7, 2025 | $0.81 | Quarterly |
| Jun 16, 2025 | Jul 8, 2025 | $0.81 | Quarterly |
| Mar 17, 2025 | Apr 7, 2025 | $0.81 | Quarterly |
| Dec 16, 2024 | Jan 8, 2025 | $0.81 | Quarterly |
| Sep 16, 2024 | Oct 7, 2024 | $0.77 | Quarterly |
| Jun 17, 2024 | Jul 8, 2024 | $0.77 | Quarterly |
| Mar 14, 2024 | Apr 5, 2024 | $0.77 | Quarterly |
| Dec 14, 2023 | Jan 8, 2024 | $0.77 | Quarterly |
| Sep 14, 2023 | Oct 6, 2023 | $0.73 | Quarterly |
| Jun 14, 2023 | Jul 10, 2023 | $0.73 | Quarterly |
| Mar 14, 2023 | Apr 10, 2023 | $0.73 | Quarterly |
| Dec 14, 2022 | Jan 9, 2023 | $0.73 | Quarterly |
| Sep 14, 2022 | Oct 7, 2022 | $0.69 | Quarterly |
| Jun 14, 2022 | Jul 8, 2022 | $0.69 | Quarterly |
| Mar 14, 2022 | Apr 7, 2022 | $0.69 | Quarterly |
| Dec 14, 2021 | Jan 7, 2022 | $0.69 | Quarterly |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Animal Health segment | $4.70B | $5.57B | $5.55B | $5.63B | $5.88B | $6.35B |
| Pharmaceutical segment | $43.02B | $42.75B | $52.01B | $53.58B | $57.40B | $58.14B |
| Other Segments | $23.0M | $382.0M | $1.73B | $907.0M | $891.0M | $515.0M |
By Geography
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Asia Pacific | $2.86B | $2.41B | $3.61B | — | $3.06B | $2.98B |
| CHINA | $3.62B | $4.38B | $5.19B | — | $5.49B | $1.94B |
| EMEA | $13.60B | $13.34B | $14.49B | — | $14.04B | $14.58B |
| JAPAN | $3.38B | $2.73B | $3.63B | — | $3.28B | $2.71B |
| Latin America | $2.27B | $2.21B | $2.58B | — | $3.46B | $3.41B |
| International | $1.23B | $1.22B | $2.57B | — | $2.56B | $2.88B |
| UNITED STATES | $21.03B | $22.43B | $27.21B | — | $32.28B | $36.51B |
| Pharmaceutical segment | — | — | — | $53.58B | — | — |
| Animal Health segment | — | — | — | $5.63B | — | — |
| Other Segments | — | — | — | $907.0M | — | — |